Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

被引：0

作者：

Kumar, Shaji ^{[1
]}

Jagannath, Sundar ^{[2
]}

Weisel, Katja C. ^{[3
]}

Dachs, Laura Rosinol ^{[4
]}

Dimopoulos, Meletios-Athanasios ^{[5
]}

Siegel, David S. ^{[6
]}

Monge, Jorge ^{[7
]}

Leleu, Xavier ^{[8
]}

Du, Juan ^{[9
]}

de la Rubia, Javier ^{[10
]}

Lee, Jae Hoon ^{[11
]}

Mateos, Maria-Victoria ^{[12
]}

Martinez, Borja Puertas ^{[12
]}

Gozzetti, Alessandro ^{[13
]}

Dytfeld, Dominik ^{[14
]}

Ocio, Enrique M. ^{[15
]}

Blade, Joan ^{[4
]}

Ozaki, Shuji ^{[16
]}

Beksac, Meral ^{[17
]}

Escalante, Fernando ^{[18
]}

Nagaraj, Madhu ^{[1
]}

Hassan, Rafla ^{[1
]}

Spin, Paul ^{[19
]}

Bonar, Nicolle ^{[19
]}

Shokoohi, Mostafa ^{[19
]}

Siddiqui, Muhaimen ^{[19
]}

Wang, Di ^{[19
]}

Hou, Kevin ^{[19
]}

Green, Jeannette ^{[20
]}

Humblet, Olivier ^{[20
]}

Breskin, Alexander ^{[20
]}

Harnett, James ^{[20
]}

Ge, Wenzhen ^{[20
]}

Sobel, Rachel E. ^{[20
]}

Jalbert, Jessica J. ^{[20
]}

Kroog, Glenn S. ^{[20
]}

Lorenc, Karen Rodriguez ^{[20
]}

Ma, Qiufei ^{[20
]}

Hampp, Christian ^{[20
]}

Durie, Brian G. M. ^{[21
]}

机构：

[1] Mayo Clin, Div Hematopathol, Rochester, MN USA

[2] MT SINAI HOSP, New York, NY USA

[3] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[4] Hosp Clin Barcelona IDIBAPS, Barcelona, Spain

[5] Univ Athens, Sch Med, Athens, Greece

[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[7] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[8] Univ Poitiers Hosp, Poitiers, France

[9] Shanghai Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China

[10] Hosp Univ I Politecn Fe, Unidad Coloproctologia, Valencia, Spain

[11] Gachon Univ, Gil Med Ctr, Incheon, South Korea

[12] Univ Hosp Salamanca, Salamanca, Spain

[13] Univ Siena, Siena, Italy

[14] Poznan Univ Med Sci, Poznan, Poland

[15] Univ Cantabria, Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[16] Tokushima Prefectural Cent Hosp, Tokushima, Japan

[17] Ankara Univ, Ankara, Turkiye

[18] Complejo Asistencial Univ Leon, Leon, Spain

[19] EVERSANA, Burlington, ON, Canada

[20] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[21] Cedars Sinai Med Ctr, Los Angeles, CA USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-200679

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7012 / 7014

页数：3

共 50 条

[1] Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites
Kumar, Shaji
Jagannath, Sundar
Weisel, Katja C.
Dachs, Laura Rosinol
Dimopoulos, Meletios-Athanasios
Siegel, David S.
Monge, Jorge
Leleu, Xavier
Du, Juan
de la Rubia, Javier
Lee, Jae Hoon
Mateos, Maria-Victoria
Gozzetti, Alessandro
Dytfeld, Dominik
Ocio, Enrique M.
Blade, Joan
Ozaki, Shuji
Nagaraj, Madhu
Hassan, Rafla
Green, Jeannette
Kroog, Glenn S.
Lorenc, Karen Rodriguez
Hampp, Christian
Ma, Qiufei
Durie, Brian G. M.
BLOOD, 2024, 144 : 7039 - 7041
[2] Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Kumar, Shaji
Weisel, Katja C.
Ma, Qiufei
Hampp, Christian
Humblet, Olivier
Shokoohi, Mostafa
Bonar, Nicolle
Spin, Paul
Harnett, James
Ge, Wenzhen
Jalbert, Jessica J.
Sobel, Rachel E.
Kroog, Glenn Scott
Rodriguez-Lorenc, Karen
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
Krishnan, Amrita Y.
Nooka, Ajay K.
Chari, Ajai
Garfall, Alfred L.
Martin, Thomas G.
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Pei, Lixia
Eric, Ammann
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok V.
Slavcev, Mary
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Jagannath, Sundar
Lee, Hans C.
Richter, Joshua Ryan
Zonder, Jeffrey A.
Hoffman, James E.
Zhou, Zheng-Yi
Horton, Viviana Garcia
Fillbrunn, Mirko
Wang, Hongjue
Mattera, Matthew
Ma, Qiufei
Inocencio, Timothy J.
Xu, Yingxin
Bergrath, Evelien
Harnett, James
Roccia, Tito
Kroog, Glenn Scott
Rodriguez-Lorenc, Karen
Houvras, Yariv
Bumma, Naresh
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Indirect Comparison of Linvoseltamab Versus Talquetamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Richter, Joshua
Jagannath, Sundar
Lee, Hans
Hoffman, James E.
Zonder, Jeffrey
Zhou, Zheng-Yi
Garcia-Horton, Viviana
Fillbrunn, Mirko
Wang, Hongjue
Mattera, Matthew
Ma, Wenxin
Ma, Qiufei
Inocencio, Timothy
Xu, Yingxin
Bergrath, Evelien
Harnett, James
Roccia, Tito
Kroog, Glenn S.
Lorenc, Karen Rodriguez
Houvras, Yariv
Bumma, Naresh
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S274 - S275
[6] Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).
Martin, Thomas G.
Krishnan, Amrita Y.
Yong, Kwee
Mehra, Katja Weisel Maneesha
Nair, Sandhya
Qi, Keqin
Londhe, Anil
Diels, Joris
Crivera, Concetta
Jackson, Carolyn Chang
Olyslager, Yunsi
Vogel, Martin
Schecter, Jordan Mark
Banerjee, Arnob
Valluri, Satish
Usmani, Saad Zafar
Berdeja, Jesus G.
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] COMPARATIVE EFFECTIVENESS OF TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN'S CHOICE OF THERAPY (RWPC) FOR PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Krishnan, A.
Nooka, A.
Chari, A.
Garfall, A. L.
Martin, T.
Nair, S.
Lin, X.
Qi, K.
Londhe, A.
Pei, L.
Ammann, E.
Chastain, K.
Parekh, T.
Marshall, A.
Slavcev, M.
Usmani, S. Z.
VALUE IN HEALTH, 2023, 26 (12) : S37 - S37
[8] External Control Analysis for KarMMa-3: Idecabtagene Vicleucel (ide-cel) vs Real-World Standard of Care (RW SoC; COTA) for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Lee, Hans
Towle, Kevin
Cope, Shannon
Liu, Sichen
Chen, Jenny
Jagannath, Sundar
Ailawadhi, Sikander
Marshall, Thomas
Acheampong, Teofilia
Dhanda, Devender
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S66 - S67
[9] Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Ye, Jing Christine
Biran, Noa
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Ammann, Eric
Renaud, Thomas
Kane, Colleen
Parekh, Trilok
Gray, Kathleen
Peterson, Steve
Costa, Luciano J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (02):
[10] Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
Krishnan, Amrita
Nooka, Ajay
Chari, Ajai
Garfall, Alfred
Martin, Thomas
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok
Marshall, Alexander
Slavcev, Mary
Usmani, Saad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S174

← 1 2 3 4 5 →